Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hormone replacement therapy: prothrombotic vs. protective effects.

Gordon D O Lowe1

  • 1Department of Medicine, Royal Infirmary, University of Glasgow, UK. gdl1j@clinmed.gla.ac.uk

Pathophysiology of Haemostasis and Thrombosis
|September 26, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations between plasma levels of coagulation factors VIII and IX and incident cardiovascular disease and mortality: systematic review and meta-analysis.

Journal of thrombosis and haemostasis : JTH·2025
Same author

Plasma viscosity, immunoglobulins and risk of cardiovascular disease and mortality: new data and meta-analyses.

Journal of clinical pathology·2023
Same author

Associations of Hemostatic Variables with Cardiovascular Disease and Total Mortality: The Glasgow MONICA Study.

TH open : companion journal to thrombosis and haemostasis·2022
Same author

Haematological variables and risk of future venous thromboembolism in the British Regional Heart Study on men. Combined D-dimer and APTT as a predictive test for thromboembolism?

British journal of haematology·2022
Same author

Cardiovascular Risk Factors Associated With Venous Thromboembolism.

JAMA cardiology·2019
Same author

Self-related Health and Blood Hypercoagulability: A Possible Mechanism for Cardiovascular Risk.

Thrombosis and haemostasis·2018
Same journal

Splenomegaly in primary antiphospholipid syndrome without accompanying portal hypertension or comorbidity.

Pathophysiology of haemostasis and thrombosis·2011
Same journal

The influence of tissue factor and tissue factor pathway inhibitor polymorphisms on thrombin generation in stable coronary artery disease.

Pathophysiology of haemostasis and thrombosis·2011
Same journal

Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients.

Pathophysiology of haemostasis and thrombosis·2011
Same journal

The effect of chronic cadmium toxicity on blood pressure and plasma viscosity.

Pathophysiology of haemostasis and thrombosis·2011
Same journal

Serum and saliva sialic acid in periodontitis patients with and without cardiovascular disease.

Pathophysiology of haemostasis and thrombosis·2011
Same journal

Plasma tissue factor levels and salivary tissue factor activities of periodontitis patients with and without cardiovascular disease.

Pathophysiology of haemostasis and thrombosis·2011
See all related articles

Hormone replacement therapy (HRT) may increase risks for heart attack and blood clots, especially with oral forms. Ongoing trials are clarifying the balance of risks and benefits for women.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Pharmacology

Background:

  • Observational studies suggest hormone replacement therapy (HRT) reduces coronary heart disease (CHD) and stroke risk.
  • Confounding factors in observational studies necessitate randomized controlled trials for accurate risk-benefit assessment of HRT.

Purpose of the Study:

  • To prospectively assess the risks and benefits of hormone replacement therapy (HRT) in secondary prevention of coronary heart disease (CHD).
  • To evaluate the prothrombotic and protective effects of various HRT preparations.

Main Methods:

  • Analysis of data from the HERS trial (Heart and Estrogen-Replacement Study) on oral HRT in secondary CHD prevention.
  • Review of prospective and case-control studies examining HRT's association with venous thromboembolism (VTE) and myocardial infarction (MI).

Related Experiment Videos

  • Assessment of HRT's impact on hemostatic factors, lipids, blood pressure, and endothelial function.

    • Main Results:

    • The HERS trial indicated an early increased risk of myocardial infarction (MI) and venous thromboembolism (VTE) with oral HRT.
    • A history of VTE or MI is now a contraindication for oral HRT.
    • Oral HRT may increase prothrombotic factors (e.g., factors VII, IX) and decrease antithrombotic factors, while transdermal HRT may have different effects.

    Conclusions:

    • Oral HRT presents an increased risk of MI and VTE, particularly in women with existing cardiovascular conditions.
    • The balance of prothrombotic and protective effects of HRT is variable and depends on the preparation and individual patient factors.
    • Ongoing large randomized trials are crucial for a comprehensive understanding of HRT's cardiovascular risks and benefits.